Key result
Essential amino acid supplementation is linked to ~40% better GLS in sarcopenic HFrEF.
Why the study?
Does essential amino acid supplementation improve cardiac and muscular performance in elderly patients with HFrEF and sarcopenia?
Does essential amino acid supplementation improve cardiac and muscular performance in elderly patients with HFrEF and sarcopenia?
Answers are grounded in this paper and cite their sources.
Early effects of essential amino acid supplementation improve cardiac and muscle performance in heart failure and sarcopenia patients, suggesting potential therapeutic benefits.
Sarcopenia is syndrome characterised by the progressive loss of muscle mass and strength, which affects approximately 20% of patients with chronic heart failure (CHF) compromising quality of life and prognosis. Today, no specific metabolic therapy exists, but these interventions may improve cardiac function and muscle performance. The aim of this study was to evaluate the early effects of supplementation with free-form essential amino-acids on cardiac and muscular performance in elderly patients with CHF and sarcopenia. We enrolled 60 caucasian patients affected by heart failure with reduced ejection fraction (HFrEF) NYHA class II (35%) and class III (65%), and sarcopenia; mean age was 80.1±1.1 years; 78% was male. Patients were on optimal medical therapy and received nutritional supplementation with essential amino acid preparations (L-Leucine 2500mg, L-Isoleucine 1250mg, L-Valine 1250mg) twice daily. A simple linear regression model was performed, with the changes in Global Longitudinal Strain (GLS) between baseline and follow-up as the dependent variable. Variables that correlated significantly were entered into a stepwise multivariate regression model to assess the degree of correlation with the dependent variable. Following 6 months of therapy we observed, a significant improvement in clinical symptoms (KCCQ-CS 60.9±1.4 vs 64.6±1.6pt, p=0.001) and enhancement in muscle and physical performance parameters (Hand grip strength increased from 18.9±5.3kg to 21.5±5.2kg, p<0.0001; Short Physical Performance Battery score increased from 5.2 ± 1.7 to 6.8±1.7 p<0.0001). The echocardiographic parameters exhibited improvement in VTDVS/BSA (from 90.1±9.0 to 82.5±9.9 ml/m2, p<0.0001); Left Ventricular Ejection Fraction (from 34.3±1.5 to 35.8±1.7. %, p<0.0001); GLS (from -8.5±1.1 to -11.9±1.2%, p<0.0001). Significant improvements were observed in HbA1c, LDL-cholesterol and triglycerides, with reduced levels of the oxidative stress biomarkers Nox-2 (from 0.7±0.1 to 0.5±0.1 nmol/L, p<0.0001) and 8-isoprostane (from 73.2±10.7 to 54.9±9.9 pg/mL, p<0.0001) and reduced circulating levels of hs-CRP (from 7.6±0.5 to 6.8±0.5 mg/l, p<0.0001). The multivariate stepwise regression model, with ΔGLS as the dependent variable, demonstrated that changes in hs-CRP, HOMA, and Nox-2 exhibited a significant correlation with the dependent variable. The entire model exhibited a correlation of 43.7% with changes in GLS. This study support the early use of essential aminoacids in patients with HFrEF and sarcopenia, confirming its clinical, biochemical and metabolic benefits and how its use can improve muscular and cardiac performance.
No takes yet. Share an insight, caveat, or question.
Armentaro et al. (2025) studied Heart failure with reduced ejection fraction (HFrEF) and sarcopenia (n=60). Essential amino acid supplementation was evaluated on Changes in Global Longitudinal Strain (GLS) (p=<0.0001). Essential amino acid supplementation for 6 months in elderly patients with HFrEF and sarcopenia improved Global Longitudinal Strain.
Synapse has enriched 10 related papers. Consider them for comparative context: